Citi's Optimism for Candel Therapeutics Reflects Biotech Growth Potential Citi analysts have initiated a Buy rating for Candel Therapeutics, setting a $25 price target. This follows promising Phase 3 results for CAN-2409 in prostate cancer, which showed significant disease-free survival improvements. Candel's pipeline, including CAN-3110 for glioma, positions it as a key player in cancer immunotherapy innovation.12